Acrescent
memantine hydrochloride / donepezil hydrochloride
Table of contents
Refused
This medicine was refused authorisation for use in the European Union.
Overview
On 18 October 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Acrescent, intended for the treatment of moderate to moderately severe Alzheimer’s disease in patients who are already taking memantine and donepezil.
The company that applied for authorisation is H. Lundbeck A/S, Denmark.
This EPAR was last updated on 11/03/2013
Application details
Product details | |
---|---|
Name |
Acrescent
|
Active substance |
|
International non-proprietary name (INN) or common name |
|
Therapeutic area (MeSH) |
Alzheimer Disease
|
Anatomical therapeutic chemical (ATC) code |
N06D
|
Application details | |
---|---|
Marketing-authorisation applicant |
H. Lundbeck A/S
|
Date of opinion |
18/10/2012
|
Date of refusal of marketing authorisation |
20/02/2013
|